Description : Progress in the treatment of cancer over the past two decades has been rapid with many new and novel therapeutic modalities arriving at an unprecedented pace. Overall cancer mortality rates have actually begun to fall in parallel with progress in the diagnosis and treatment of malignant disease. Despite our advances in the understanding of the biology and molecular genetics of cancer, as well as the availability of an increasing array of effective therapies, cancer treatment today and for the foreseeable future will include the traditional modalities of surgery, radiation therapy and chemotherapy. Myelosuppressive agents with their potential hematopoietic toxicities remain the mainstay of systemic treatment for both metastatic and early stage cancer. The complications of cancer chemotherapy have serious impact on a patient’s well being and overall quality of life. Fortunately, advances in cancer treatment have been accompanied by equally impressive progress in the availability of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of potentially curative cancer treatment. Despite the increasing complexity of modern cancer treatment, it is the obligation of the oncologist as well as the entire cancer care team to be certain that cancer patients receive the optimal supportive care available for their disease and its treatment. Among the most serious and potentially life threatening toxicities of cancer treatment are the hematologic toxicities accompanying myelosuppression including anemia and associated asthenia and fatigue, neutropenia and fever associated with infection in the immunocompromised patient and thrombocytopenia and accompanying risk of bleeding. Special supportive care needs arise in the very elderly care patient that may tax the ability of even the most skilled clinician. Despite the considerable progress that has been made with more effective and safer treatment strategies, myelosuppressive chemotherapy will remain the mainstay of systemic treatment for cancer for the foreseeable future. While considerable progress has occurred, better methods and broader application of supportive care measures are needed to reduce the symptomatic effects of cancer and the associated toxicities associated with cancer treatment. No area of cancer supportive care better illustrates the progress that has resulted from advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of the hematopoietic growth factors. This volume will review and integrate the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. The current clinical utilization of these agents is based on numerous randomized controlled trials and meta-analyses along with evidence-based clinical practice guidelines developed by professional societies guiding their appropriate and cost-effective use in clinical care.
Description : Whether to promote platelet recovery or to ameliorate the complications of cancer and the side effects of chemotherapy, hematopoietic growth factors (HGFs) now account for more than $5 billion per year of the US health care budget. In Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics, leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem-cell factor and its receptor, c-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonists in oncology. Comprehensive and up-to-date, Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Practice offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombocytopenia in patients with malignant and nonmalignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit.
Description : The contributors to this volume deliver information on latest drug treatments and therapeutic approaches for a wide range of diseases and conditions. Coverage includes discussion of racial, ethnic, and gender differences in response to drugs and to biotechnical, pediatric and neonatal therapies.
Description : This book provides a thorough and up-to-date discussion of key issues in the supportive care of children with cancer. A variety of frequently encountered situations is covered, including infections, metabolic, cardiopulmonary and neurologic emergencies, tumor lysis syndrome, pain, emesis, mucositis, thrombotic disorders, nutritional problems, hyperleukocytosis and acute abdomen. Throughout the emphasis is firmly on evidenced-based guidance developed from the relevant literature. Information is presented in a manner that will enable readers quickly to locate advice when confronted by a supportive care problem in one of their patients. Helpful algorithms are provided and important “take home points” are highlighted in figures and tables. Supportive Care in Pediatric Oncology will be an invaluable source of assistance for a wide range of health professionals involved in pediatric cancer care.
Description : Written by the leading names in pediatric oncology and hematology, Nathan and Oski’s Hematology and Oncology of Infancy and Childhood offers you the essential tools you need to overcome the unique challenges and complexities of childhood cancers and hematologic disorders. Meticulously updated, this exciting full-color set brings together the pathophysiology of disease with detailed clinical guidance to provide you with the most comprehensive, authoritative, up-to-date information for diagnosing and treating children. Consult this title on your favorite e-reader, conduct rapid searches, and adjust font sizes for optimal readability. Form a definitive diagnosis and create the best treatment plans possible with comprehensive coverage of all pediatric cancers, including less-common tumors, as well as all hematologic disorders, including newly recognized ones. Develop a thorough, understanding of the underlying science of diseases through summaries of relevant pathophysiology balanced with clear, practical clinical guidance. Nathan and Oski’s is the only comprehensive product on the market that relates pathophysiology in such depth to hematologic and oncologic diseases affecting children. Quickly and effortlessly access the key information you need with the help of a consistent organization from chapter to chapter and from volume to volume. Stay at the forefront of your field thanks to new and revised chapters covering topics such as paroxysmal nocturnal hemoglobinuria, lysosomal storage diseases, childhood genetic predisposition to cancer, and oncology informatics. Learn about the latest breakthroughs in diagnosis and management, making this the most complete guide in pediatric hematology and oncology. Discover the latest in focused molecularly targeted therapies derived from the exponential growth of knowledge about basic biology and genetics underlying the field. Rely on it anytime, anywhere!
Description : Cancer Nursing: Principles and Practice, Eighth Edition continues as the gold standard in oncology nursing. With contributions from the foremost experts in the field, it has remained the definitive reference on the rapidly changing science and practice of oncology nursing for more than 25 years. Completely updated and revised to reflect the latest research and developments in the care of patients with cancer, the Eighth Edition includes new chapters on the biology of cancer, sleep disorders, and palliative care across the cancer continuum. The Eighth Edition also includes significant updates to the basic science chapters to reflect recent increases in scientific knowledge, especially relating to genes and cancer. Also heavily revised are the sections devoted to the dynamics of cancer prevention, detection, and diagnosis, as well as treatment, oncologic emergencies, end of life care, and professional and legal issues for oncology nurses.
Description : Title consistently uses the evidence-based approach Evidence-based tables make documentation of care plan easy Interdisciplinary orientation – all aspects of patient care are covered Only book that involves experts from the entire range of cancer treatment in the fields of medical, surgical and radiation oncology Includes hot topics such as prevention and breast cancer Offers ground-breaking sections on the latest research and clinical applications in cancer survivorship Chapter on PET addresses imaging issues and how to get the best results Most comprehensive sections on the biology and epidemiology of cancer as compared to competitors
Description : Transforming Growth Factor- ß in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ß (TGF- ß) in cancer treatment and therapy. The first volume, Basic and Clinical Biology, is divided into three parts. This volume’s companion, Cancer Treatment in Therapy, examines transforming growth factor- ß in other developing and advanced cancers and methods of treatment and therapy.